Tags

Type your tag names separated by a space and hit enter

Improved treatment satisfaction but no difference in metabolic control when using continuous subcutaneous insulin infusion vs. multiple daily injections in children at onset of type 1 diabetes mellitus.
Pediatr Diabetes. 2008 Oct; 9(5):472-9.PD

Abstract

OBJECTIVE

The aim of this study was to compare safety, metabolic control, and treatment satisfaction in children/adolescents at onset of type 1 diabetes mellitus who were treated with either continuous subcutaneous insulin infusion (CSII) or multiple daily injections (MDI).

RESEARCH DESIGN AND METHODS

Seventy-two children/adolescents (7-17 yr of age) were enrolled in this open, randomized, parallel, multicenter study. Approximately half of the patients were treated with MDI (natural protamine hagedorn [NPH] insulin twice daily and rapid-acting insulin three to -four times daily, n = 38) by pen, and the other half received CSII (n = 34). The patients were followed for 24 months with clinical visits at the entry of the study and after 1, 6, 12, and 24 months. During these visits, hemoglobin A1c, insulin doses, weight, and height were registered. Severe episodes of hypoglycemia and ketoacidosis as well as technical problems were recorded. In addition, the patients/parents answered the Diabetes Treatment Satisfaction Questionnaire.

RESULTS

There was no significant difference in metabolic control between the treatment groups. Treatment satisfaction was significantly higher in the group treated with CSII compared with the MDI group (p <or= 0.01 at all screening visits). There were no episodes of ketoacidosis and there was no significant difference regarding severe hypoglycemia between the treatment groups.

CONCLUSIONS

CSII treatment proved to be a safe therapy in children/adolescents followed for 24 months after onset of their diabetes. Treatment satisfaction was higher in the CSII group, although there was no difference in metabolic control compared with the MDI group.

Authors+Show Affiliations

Department of Pediatrics, Gävle Hospital, Gävle, Sweden. lars.skogsberg@lg.seNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18721168

Citation

Skogsberg, Lars, et al. "Improved Treatment Satisfaction but No Difference in Metabolic Control when Using Continuous Subcutaneous Insulin Infusion Vs. Multiple Daily Injections in Children at Onset of Type 1 Diabetes Mellitus." Pediatric Diabetes, vol. 9, no. 5, 2008, pp. 472-9.
Skogsberg L, Fors H, Hanas R, et al. Improved treatment satisfaction but no difference in metabolic control when using continuous subcutaneous insulin infusion vs. multiple daily injections in children at onset of type 1 diabetes mellitus. Pediatr Diabetes. 2008;9(5):472-9.
Skogsberg, L., Fors, H., Hanas, R., Chaplin, J. E., Lindman, E., & Skogsberg, J. (2008). Improved treatment satisfaction but no difference in metabolic control when using continuous subcutaneous insulin infusion vs. multiple daily injections in children at onset of type 1 diabetes mellitus. Pediatric Diabetes, 9(5), 472-9. https://doi.org/10.1111/j.1399-5448.2008.00390.x
Skogsberg L, et al. Improved Treatment Satisfaction but No Difference in Metabolic Control when Using Continuous Subcutaneous Insulin Infusion Vs. Multiple Daily Injections in Children at Onset of Type 1 Diabetes Mellitus. Pediatr Diabetes. 2008;9(5):472-9. PubMed PMID: 18721168.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Improved treatment satisfaction but no difference in metabolic control when using continuous subcutaneous insulin infusion vs. multiple daily injections in children at onset of type 1 diabetes mellitus. AU - Skogsberg,Lars, AU - Fors,Hans, AU - Hanas,Ragnar, AU - Chaplin,J E, AU - Lindman,Elisabeth, AU - Skogsberg,Josefin, Y1 - 2008/08/20/ PY - 2008/8/30/pubmed PY - 2008/12/17/medline PY - 2008/8/30/entrez SP - 472 EP - 9 JF - Pediatric diabetes JO - Pediatr Diabetes VL - 9 IS - 5 N2 - OBJECTIVE: The aim of this study was to compare safety, metabolic control, and treatment satisfaction in children/adolescents at onset of type 1 diabetes mellitus who were treated with either continuous subcutaneous insulin infusion (CSII) or multiple daily injections (MDI). RESEARCH DESIGN AND METHODS: Seventy-two children/adolescents (7-17 yr of age) were enrolled in this open, randomized, parallel, multicenter study. Approximately half of the patients were treated with MDI (natural protamine hagedorn [NPH] insulin twice daily and rapid-acting insulin three to -four times daily, n = 38) by pen, and the other half received CSII (n = 34). The patients were followed for 24 months with clinical visits at the entry of the study and after 1, 6, 12, and 24 months. During these visits, hemoglobin A1c, insulin doses, weight, and height were registered. Severe episodes of hypoglycemia and ketoacidosis as well as technical problems were recorded. In addition, the patients/parents answered the Diabetes Treatment Satisfaction Questionnaire. RESULTS: There was no significant difference in metabolic control between the treatment groups. Treatment satisfaction was significantly higher in the group treated with CSII compared with the MDI group (p <or= 0.01 at all screening visits). There were no episodes of ketoacidosis and there was no significant difference regarding severe hypoglycemia between the treatment groups. CONCLUSIONS: CSII treatment proved to be a safe therapy in children/adolescents followed for 24 months after onset of their diabetes. Treatment satisfaction was higher in the CSII group, although there was no difference in metabolic control compared with the MDI group. SN - 1399-5448 UR - https://www.unboundmedicine.com/medline/citation/18721168/Improved_treatment_satisfaction_but_no_difference_in_metabolic_control_when_using_continuous_subcutaneous_insulin_infusion_vs__multiple_daily_injections_in_children_at_onset_of_type_1_diabetes_mellitus_ L2 - https://doi.org/10.1111/j.1399-5448.2008.00390.x DB - PRIME DP - Unbound Medicine ER -